摘要
目的:探讨α1受体阻滞剂在经皮肾镜术后应用的临床意义和初步经验。方法:回顾性分析2008年1月~2011年3月对67例肾结石患者行经皮肾镜术的临床资料,患者术后拔除肾造瘘管与尿管后分为两组:A组32例(服用α受体阻滞剂1周),B组35例。结果:A组患者血尿的发生率和持续时间、肋腹区疼痛、尿频/尿急的发生率与B组的差异有统计学意义。结论:经皮肾镜术后服用α1受体阻滞剂有利于防治双J管综合征。
Objective: To evaluate clinical efficacy of alpha1 blocker after Percutaneots nephrostolithotomy. Methods:From January 2008 to March 2011, 67 patients who underwent Percutaneots nephrostolithotomy were analysed retrospectively. The patients without nephrostomy tube and catheter divided into two groups, group A, 32 patients were with use of alphal blocker for 1 week , and group B, 35 patients without use of alpha1 blocker. Results:The incidences of Hematuria, flank/abdominal pain, frequency/urgency were statistically different among the two groups. Conclusions: Alpha1 blocker after Percutaneots nephrostolithotomy is a safe and less traumatic method for treating Ureteral stent symptom.
出处
《临床泌尿外科杂志》
北大核心
2011年第12期919-921,共3页
Journal of Clinical Urology
基金
贵州省卫生厅优秀医学青年基金项目(NO:gzwkj2008-2-009与黔卫发2006-130)
关键词
肾结石
经皮肾镜
α_1受体阻滞剂
双J管综合征
kidney stones percutaneots nephrostolithotomy
alphal blockers ureteral stent symptom